Presenter
Laura Esserman, MD, MBA
Alfred A. de Lorimier Endowed Chair in General Surgery
Professor of Surgery and Radiology
Director, UCSF Breast Care Center;
Co-Leader, Breast Oncology Program
UCSF Helen Diller Family Comprehensive Cancer Center;
University of California, San Francisco

 

Speaker
Jennifer Swenson, DO
Senior Medical Director, Strategic Partner Operations
Optum

About the presenter
Laura Esserman, MD, MBA, is professor of surgery and radiology at the University of California, San Francisco (UCSF) and director of the UCSF Breast Care Clinic. Her work in breast cancer prevention and/or treatment spans the spectrum from basic science to public policy issues and the impact of both on the delivery of clinical care. Dr. Esserman is recognized as a thought leader in cancer screening and over-diagnosis, as well as innovative clinical trial design. She led the creation of the University of California-wide Athena Breast Health Network, a learning system designed to integrate clinical care and research as it follows 150,000 women from screening through treatment and outcomes. The Athena Network launched the PCORI-funded Wisdom Study, which tests a personalized approach to breast cancer screening in 100,000 women. She is also a leader of the innovative I-SPY TRIAL model, designed to accelerate the identification and approval of effective new agents for women with high-risk breast cancers. In 2020, she got FDA approval for an I-SPY COVID trial, designed to rapidly screen and confirm high-impact treatments to reduce mortality and time on ventilators.

Activity planners
Elizabeth Albert, MD
Clinical Activity Manager
Optum Health Education

Sarah Chart, RN
Vice President
Optum Health Education

Joshua Jacobs, MD, FAAFP
National Medical Director
Optum Health

Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Optum Health Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.

Dr. Esserman has disclosed the following: Moderna (Grant/Research Support); Blue Cross/Blue Shield (Advisory Board)

All relevant financial relationships have been mitigated.